Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Cuts Price Target on Immune Design (IMDZ) to $15 Following 3Q
November 10, 2016 9:14 AM ESTJefferies maintained a Buy rating on Immune Design (NASDAQ: IMDZ), and cut the price target to $15.00 (from $17.00), following the company's 3Q earnings report. IMDZ provided an update indicating that the follow up for CMB305 is 7.4 mo and LV305 is 21.3 mo. Safety also continues to... More
